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Adipose tissue dysfunction is an important determinant
of obesity-associated, lipid-induced metabolic compli-
cations. Ceramides are well-known mediators of lipid-
induced insulin resistance in peripheral organs such as
muscle. DEGS1 is the desaturase catalyzing the last step
in the main ceramide biosynthetic pathway. Functional
suppression of DEGS1 activity results in substantial
changes in ceramide species likely to affect fundamental
biological functions such as oxidative stress, cell sur-
vival, and proliferation. Here, we show that degs1 ex-
pression is specifically decreased in the adipose tissue
of obese patients and murine models of genetic and nu-
tritional obesity. Moreover, loss-of-function experiments
using pharmacological or genetic ablation of DEGS1 in
preadipocytes prevented adipogenesis and decreased
lipid accumulation. This was associated with elevated
oxidative stress, cellular death, and blockage of the cell
cycle. These effects were coupled with increased dihy-
droceramide content. Finally, we validated in vivo that
pharmacological inhibition of DEGS1 impairs adipocyte
differentiation. These data identify DEGS1 as a new
potential target to restore adipose tissue function and
prevent obesity-associated metabolic disturbances.
Dysfunction of white adipose tissue (WAT) and impaired
differentiation of new adipocytes may lead to lipid leakage
and inappropriate accumulation of ectopic lipids in
peripheral organs, causing lipotoxicity and the metabolic
syndrome (1). The toxic effects of lipids are determined
by both their quantity and their qualitative characteristics
(2). Whereas it is well documented that specific species of
sphingolipids and ceramides (Cers) mediate lipotoxicity in
liver and muscle (3,4), the contribution of specific lipotoxic
species to WAT dysfunction in the context of obesity is still
not well defined. It is known that in rodent WAT, Cers
increase in response to a high-fat diet (HFD) (5,6) concom-
itantly with the onset of insulin resistance (6). Lipid anal-
ysis of WAT from human obese subjects has produced
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conflicting results, showing either increased or decreased
Cer levels in obese and insulin-resistant patients (7,8).
Cers can be synthesized from sphingomyelins, but the
main contributor to their biosynthesis is the de novo
pathway. The final reaction of the de novo pathway is
catalyzed by a D4-dihydroceramide (DhCer) desaturase
(DEGS1) that adds a 4,5-trans-double bound on the sphin-
goid base of the DhCer (9). The other enzyme, DEGS2,
catalyzes the synthesis of phytoceramides (10), whose
expression is restricted to skin, intestine, and kidney.
There is evidence that downregulation of degs1 in-
creases the DhCer/Cer ratio in different cellular models.
Although DhCer was considered an inactive precursor
of Cers (11), recent studies (12,13) have suggested their
relevance as modulators of cell cycle, apoptosis, autophagy,
or oxidative stress, processes that a priori are expected
to compromise the development and function of adipose
tissue (AT).
Since DEGS1 is the key enzyme regulating the DhCer/
Cer ratio, understanding its regulation is important in
determining the pathophysiological relevance of this path-
way in AT. Of note, degs1 has recently been identified
in genome-wide association studies as a candidate gene
associated with fat mass accumulation in mice (14), fur-
ther suggesting that DEGS1 may be relevant for the
adaptive accretion of AT. Moreover, DEGS1 could be
considered an attractive therapeutic target for obesity-
associated insulin resistance, since fenretinide has been
claimed to improve insulin sensitivity by inhibiting
DEGS1 (15), although other molecular targets cannot
be ruled out.
Here we show that DEGS1 expression is selectively
perturbed in the WAT of murine models of nutritional
and genetically induced obesity and in the WAT of mor-
bidly obese (MO) patients. In vitro analysis revealed that
both pharmacological inhibition and genetic ablation of
DEGS1 result in impaired adipocyte differentiation and
lipid accumulation, effects mediated by increased DhCer
content. In vivo, pharmacological inhibition of DEGS1
also resulted in impaired adipocyte differentiation. De-
creased levels of DEGS1 were associated with increased
oxidative stress, accelerated cellular death, and blockage
of cell cycle. We also show data supporting that DEGS1
expression is regulated by peroxisome proliferator–
activated receptor (PPAR)g.
RESEARCH DESIGN AND METHODS
Mice Husbandry
Animals were housed at 22–24°C with 12-h light/dark cycles.
Food and water were available ad libitum. Lean wild-type
(WT), PPARg22/2, and PPARg2/ob/ob double knockout
mice (16) were used for profiling purposes. Mice were fed
a normal chow diet (D12450B) or an HFD (D12451) from
Research Diets.
For the pharmacological inhibition of DEGS1, 10-week-
old male C57BL/6 WT mice were used. Mice were fed
an HFD for 5 weeks before C8-cyclopropenylceramide
(C8-CPPC) (Matreya) administration. All protocols used
were approved by the U.K. Home Office.
Intraperitoneal Injection of Cyclopropenylceramide
Mice were distributed in two groups (n = 8) and admin-
istered daily vehicle (2-hydroxypropyl betacyclodextrine)
or C8-CPPC (2 mg/kg/day) for 9 days via intraperitoneal
injection. Mice were culled at the end of the experiment,
and WAT was removed for gene expression and micros-
copy analysis. No differences in food intake, lean mass,
and fat content were observed during the treatment.
Ex Vivo Experiments in Isolated Mature Adipocytes
Adipocytes from gonadal WAT of 16-week-old C57BL/6 mice
were obtained by collagenase type II digestion at 37°C. After
digestion, adipocytes were placed in DMEM with or without
1 mmol/L C8-CPPC every 5 h for a total period of 20 h.
Retroviral Short Hairpin RNA Constructs for DEGS1
RNAi-Ready pSIREN-RetroQ vectors (BD Biosciences)
were used to target degs1 in 3T3-L1 cells. Sequences tar-
geting degs1 were ligated into the pSIREN vector as de-
scribed in the manufacturer’s instructions. Retroviruses
were generated by transfecting BOSC cells (American
Type Culture Collection) with the pSIREN plasmids using
FuGene6 (Roche). Supernatant with the viral content was
used to transfect 3T3-L1 preadipocytes. Twenty-four
hours after retroviral infection, the cells were selected
with puromycin (4 mg/mL).
Culture, Differentiation, and Treatment of 3T3-L1
Preadipocytes
Cells were differentiated into adipocytes (day 9) accord-
ingly to the protocol described by Roberts et al. (17) with
or without rosiglitazone 0.1 mmol/L. Lipid accumulation
was assessed by Oil Red O solution (18).
Pharmacological Inhibition of DEGS1 Activity In Vitro
Effects on Differentiation
At day 0 of differentiation, 3T3-L1 cells were treated with
C8-CPPC 1 mmol/L and/or rosiglitazone 0.1 mmol/L for 96 h.
Effects on Lipolysis
On day 8 of differentiation, after 48 h of treatment with
C8-CPPC 1 mmol/L, the cells were exposed to norepineph-
rine (NE) (1028 and 1027 mol/L) for 6 h.
Effects on Insulin Signaling
On day 8 of differentiation, after 48 h of treatment with
C8-CPPC 1 mmol/L, the cells were exposed to insulin (10
and 100 nmol/L) for 15 min.
Effects on GLUT4 and Adiponectin
On day 8 of differentiation, after 48 h of treatment with
C8-CPPC 0.5–1 mmol/L, the cells were exposed to insulin.
Effects on AMPK
On day 8 of differentiation, after 48 h of treatment with
C8-CPPC 0.5–1 mmol/L, the cells were exposed to insulin
(10 and 100 nmol/L), rosiglitazone (1 and 10 nmol/L),
and metformin (100 nmol/L) for 24 h.
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DhCer Treatment
3T3-L1 preadipocytes were treated at day 0 of differentia-
tion with the induction cocktail and C2DhCer at 50 mmol/L
for 3 days, and a second batch of cells were exposed at day 3
of differentiation and treated with C2DhCer at 50 mmol/L
for 3 days. All batches were taken until final differentiation
at day 9.
Human Samples
The cohort included 28 MO and 6 nonobese subjects with
no alterations to lipid or glucose metabolism as control
subjects (Table 1). Approval for the study was given by the
ethics committee, and all patients gave their informed
consent. Visceral AT biopsy samples were obtained from
MO patients undergoing bariatric surgery (Scopinaro pro-
cedure) or laparoscopic surgery (hiatus hernia repair or
cholecystectomies) for the lean subjects.
Western Blotting
Protein extracts were prepared using the Nuclear and
Cytoplasmic Extraction Reagents Kit (Pierce) according to
the manufacturer’s instructions. Immunoblots were incu-
bated with the following antibodies: PPARg, C/EBPb, and
CyclinA (Santa Cruz Biotechnology); CyclinB1, D1, D3 and
E1, cdk4, AKT, Ser473-pAKT, p44/42 MAPK, phospho-
p44/42 MAPK, Ser660-pHSL (p-hormone-sensitive lipase),
Ser565-pHSL, total HSL, ATGL, caveolin-1, plin1, glut4, adi-
ponectin, and AMPK (Cell Signaling Technology); and adfp/
adrp, abhd5, and anti-b-actin (Abcam).
RT-PCR
RNA was extracted using TRI Reagent (Sigma) and reverse
transcribed to cDNA. Real-time PCR using SYBRgreen
was performed according to the manufacturer’s instruc-
tions (ABI). Primer sequences were obtained from Primer
Blast (19). Expression of genes was corrected by the
geometrical average of 18s, b2m, b-act, and 36b4 using
Bestkeeper (20).
Apoptosis: Combined Annexin V/Propidium Iodide
Staining
Viability was assessed by using an Annexin V/propidium
iodide kit (Bender MedSystems), according to the manufac-
turer’s recommendations. Binding of fluorescein-conjugated
Annexin V and propidium iodide was measured by FACSCalibur
(BD Biosciences).
Cellular Proliferation
Cell viability was assessed using an colorimetric assay
(Roche) following the protocol supplied by the manufac-
turer. Cell proliferation was analyzed by quantification of
the incorporation of BrdU (Roche).
Boron-Dipyrromethene Staining, Reactive Oxygen
Stress Production, and Mitochondrial Content
Cells were incubated with boron-dipyrromethene (BODIPY)
at 4°C or alternatively with 20 mmol/L 29,79-dichlorodihy-
drofluorescein diacetate or 100 nmol/L Mitotracker (Invi-
trogen) at 37°C for 30 min and analyzed on a FACSCalibur
cell analyzer.
Cellular Oxygen Consumption
Cells were exposed to oligomycin (1 mmol/L), C8-CPPC
(0.9 mmol/L), and antimycin/rotenone (1 mmol/L each);
O2 consumption was measured using the XF24 analyzer
(Seahorse Bioscience) for a period of 90 min.
Whole-Mount Confocal Microscopy
Gonadal AT was fixed in 4% paraformaldehyde. Samples
were incubated at 4°C with mouse Pref-1 (preadipocyte
factor-1) or rabbit Ki67 primary antibodies. Nuclei and
neutral lipids were stained with Hoechst 33342 and BODIPY
493/503, respectively. Sample examination was performed
using a Zeiss 510 confocal laser scanning microscope (Carl
Zeiss). Pref-1+, Ki67+, and BODIPY+ cells and total cells (up
to 913 cells/field) were automatically counted by using
ImageJ software in three independent fields in each tissue.
Light Microscopy Analysis
Samples for AT hematoxylin-eosin staining were prepared
as described previously (16). Adipocyte sizes were mea-
sured using Cell P (Olympus Soft Imaging Solutions
GmbH). Between 1,000 and 3,000 adipocytes from each
mouse were used to obtain the mean cell area.
Luciferase Reporter Assay
Human embryonic kidney 293 cells were transfected
using Lipofectamine LTX (Invitrogen), following the
manufacturer’s instructions. Seventy-five nanograms of
the reporter plasmid (3xPPRE TKLuc) and 37.5 ng of the
eukaryotic expression vector (pSV-PPARg) were cotrans-
fected to each well. The plasmid pRL-CMV (5 ng/well)
was included as an internal control. Twenty-four hours
post-transfection, cells were treated as indicated (DMSO,
rosiglitazone, 10 mmol/L; GW1929, 10 mmol/L; and
C2DhCer, C16DhCer, and Cer, 100 mmol/L). Luciferase
assays were performed using the dual luciferase reporter
assay system (Promega).
Table 1—Clinical characteristics of control subjects and MO
patients




Age, years 52.17 6 5.1 41.57 6 2.96
Weight, kg 74.00 6 0.71 155.5 6 7.32
Height, cm 162.60 6 1.60 165.53 6 2.49
BMI, kg/m2 25.04 6 0.55 56.51 6 1.68
Serum insulin, IU/mL 11.23 6 1.58 30.09 6 2.30
HOMA-IR 3.51 6 0.48 8.18 6 0.78
Serum glucose, mmol/L 6.03 6 0.32 5.74 6 0.26
Serum cholesterol, mmol/L 4.68 6 0.40 4.92 6 0.25
HDL cholesterol, mmol/L 0.97 6 0.23 1.10 6 0.09
Triglycerides, mmol/L 1.08 6 0.20 1.42 6 0.19
Values are reported as the mean 6 SEM, unless otherwise in-
dicated. HOMA-IR, HOMA of insulin resistance.
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Lipidomics
Cells were mixed with 0.9% NaCl and sonicated for 5 min
at 5°C and 40 kHz. Samples were spiked with internal
standard. The samples were extracted with chloroform:
methanol (2:1). The lower phase was collected and mixed
with the labeled standard mixture (three stable isotope-
labeled reference compounds). Lipid extracts were ana-
lyzed on a Q-ToF Premier Mass Spectrometer (Waters)
combined with an Acquity Ultra Performance Liquid
Chromatography/Mass Spectrometry system (Waters).
The data were processed using MZmine software. The
lipids were quantified by normalizing with correspond-
ing internal standard.
Statistical Analysis
Student t test (unpaired), ANOVA, and Duncan test were
used for the statistical analysis. Statistical significance was
set at P , 0.05 and P , 0.01. The Spearman correlation
was calculated to estimate the linear correlations between
variables at P , 0.01.
RESULTS
DEGS1 Is Downregulated in WAT in Obese Murine
Models
Tissue distribution analysis showed that degs1 is present
in most tissues, and it is particularly highly expressed in
AT, liver, and muscle, whereas degs2 mRNA is detected
only in intestine (Fig. 1A). Degs1 expression in vivo was
positively correlated with WAT mass in lean healthy mice
(Fig. 1B). However, this correlation was disrupted in mu-
rine models of nutritional and genetically induced obesity
(HFD and ob/ob), where degs1 mRNA expression was de-
creased versus controls (Fig. 1C and F). Of note, the dys-
regulation of degs1 in obesity was limited to WAT, as its
expression in liver or skeletal muscle was not affected in
either HFD-fed mice (Fig. 1D and E) or ob/ob mice (Fig.
1G and H). DEGS1 was preferentially expressed in ma-
tured adipocytes versus stromal vascular fraction in lean
and ob/ob mice (Supplementary Fig. 1), and downregulated
in ob/ob adipocytes versus lean adipocytes. Moreover, this
downregulation of degs1 in total WAT of HFD-fed and ob/ob
mice was also recapitulated in visceral AT of MO patients
(Supplementary Fig. 2A).
To determine whether the decrease in degs1 expression
was part of a global adaptation of de novo Cer synthesis
pathway in obesity, the expression of other genes in this
pathway was measured. Expression of the sptlc1 and sptlc2
subunits was not changed in human visceral AT or in ob/ob
WAT, but sptlc2 expression was increased in HFD WAT
(Supplementary Fig. 2B and C). Moreover, both HFD and
ob/ob mouse WAT exhibited a reduction in a subset of Cer
synthases, suggesting a possible defect in the synthesis of
a specific subset of Cers.
We then confirmed that modulators of obesity-associated
inflammation may contribute to the downregulation of
degs1, as treatment of 3T3-L1 adipocytes with tumor
necrosis factor-a (5 and 10 ng/mL) for 48 h resulted in
a dose-dependent downregulation of degs1 mRNA
expression (38.8 6 3.6% and 45.7 6 7.3% reduction,
respectively).
We then investigated a link between DEGS1 and the
adipogenic program. It is known that obese and insulin-
resistant murine models and humans have reduced
expression of pparg2 in WAT. Furthermore we observed
that expression of pparg2 and degs1 was directly corre-
lated in 3T3-L1 after treatment with rosiglitazone (Sup-
plementary Fig. 3A). To validate this in vivo, we analyzed
the regulation of degs1 in AT, liver, and skeletal muscle of
pparg2KO and POKO mice (16). WAT of pparg2KO and
POKO mice expressed significantly lower degs1 mRNA
levels compared with WT mice (Supplementary Fig. 3B).
This association was restricted to WAT since the expres-
sion of degs1 in other metabolic organs such as skeletal
muscle or liver was not affected when pparg2 was absent
(Supplementary Fig. 3C and D).
DEGS1 Controls Important Cellular Functions Such as
Proliferation, Survival, and Oxidative Stress in 3T3-L1
Adipocytes
A stable degs1 knockdown 3T3-L1 cell line (65%) (Fig. 2A)
resulted in inhibition of cell growth after 24 h (Fig. 2B and
C). Degs1 knockdown also induced cell death (13.7%) and
apoptosis (6.3%) (Fig. 2E). These were associated with a de-
crease in cyclin-A and cdk2 levels in degs1 KD proliferat-
ing cells (Fig. 2F), as well as elevated levels of Bax and
caspase-3 mRNA (Fig. 2D). Elevated reactive oxygen species
production (Fig. 2I) along with an upregulation of the ex-
pression of antioxidant genes were observed in degs1 KD
preadipocytes (Fig. 2H). This was accompanied by impaired
mitochondrial oxygen consumption (Fig. 2G) without
changes in the number of mitochondria (Fig. 2J).
DEGS1 Is Required for Adipocyte Differentiation
Expression of degs1 is increased during normal differen-
tiation of 3T3-L1 adipocytes (Fig. 3A). To investigate
whether ablation of DEGS1 affected adipogenesis, 3T3-L1
degs1 KD cells were induced to differentiate. At day 9,
degs1 KD cells showed impaired lipid accumulation versus
controls (Fig. 3B). Moreover, pref1 mRNA expression,
a marker for preadipocytes, was not decreased in degs1
KD cells at day 9, suggesting that a relevant number of
cells remained in the preadipocyte stage (Fig. 3C). In ad-
dition, the expressions of proadipogenic and lipogenic
genes were downregulated (Fig. 3D). Interestingly, treat-
ment with rosiglitazone only partially improved the dif-
ferentiation and lipid accumulation rates of degs1 KD cells
(Supplementary Fig. 4A and B).
We tested whether DEGS1 expression may affect the
mitotic clonal expansion (MCE). In degs1 KD cells, pparg
and cebpb were downregulated compared with controls at
time 0 and 24 h following differentiation induction (Sup-
plementary Fig. 5A and B). The expression of PPARg and
several cyclins involved in adipogenesis were measured at
earlier time points. We noted a strong effect of degs1
depletion on PPARg2 mRNA from time 0. Additionally,
reduced levels of degs1 blocked MCE, as indicated by the
diabetes.diabetesjournals.org Barbarroja and Associates 1183
inhibition of cyclin D1 and cdk2 expression between time
0 and 4 h after the induction (Supplementary Fig. 5A and
B). Cyclin E and cyclin D3 expression was also inhibited,
but at later time points.
Pharmacological Inhibition of DEGS1 Recapitulates
DEGS1 KD Antiadipogenic Phenotype
Use of C8-CPPC, a selective inhibitor of DEGS1 (21) fur-
ther confirmed the relevance of DEGS1 in adipogenesis.
Similarly to degs1 KD cells, 3T3-L1 cells were induced to
differentiate and were treated simultaneously with
C8-CPPC from time 0 h every 6 h for 48 h. C8-CPPC de-
creased the expression of proadipogenic transcription fac-
tors such as PPARg and C/EBPb as well as lipogenic genes
(Fig. 4A and C). The antiadipogenic effect of C8-CPPC per-
sisted after rosiglitazone treatment (Fig. 4A and C). As
expected, analysis of neutral lipids showed that 3T3-L1 cells
treated with C8-CPPC for 96 h accumulated significantly
less lipids compared with untreated cells (Fig. 4D).
Pharmacological Inhibition of DEGS1 Also Impairs
Adipocyte Differentiation In Vivo
We administered C8-CPPC intraperitoneally to mice fed
an HFD for 5 weeks, an experimental protocol that is
known to trigger adipocyte hyperplasia. Molecular analysis
of the WAT from mice treated with C8-CPPC presented
higher levels of pref-1+ cells, suggesting an increase in the
number of preadipocytes compared with controls. Inter-
estingly, a significant number of preadipocytes showed
evidence of increased proliferation (Ki67+), whereas the
number of differentiating preadipocytes (pref1+, BODIPY+)
was significantly smaller in comparison with controls (Fig.
5A). These data were reinforced at the mRNA level by
showing increased expression of pref-1 and gata2 (Fig.
5B), and the presence of fewer small adipocytes in treated
mice (Supplementary Fig. 6). Altogether, these data sug-
gest that C8-CPPC–mediated inhibition of DEGS1 im-
paired the capacity of preadipocytes to differentiate into
adipocytes in vivo.
Figure 1—A: Tissue distribution of degs1. B: Correlation of degs1 mRNA expression and fat pad size. The Spearman correlation coef-
ficients were calculated to estimate the linear correlations between variables. The rejection level for a null hypothesis was P < 0.01. Data
are from 14 lean mice. C–E: Expression levels of degs1 mRNA in response to HFD. F–H: Expression levels of degs1 mRNA in ob/ob mice.
Values are the mean 6 SEM for six to eight animals per group. *P < 0.05 vs. WT. AU, arbitrary units; BAT, brown AT; gWAT, gonadal WAT;
IngFat, inguinal fat; RetroFat, retroperitoneal fat; SKM, skeletal muscle.
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DEGS1 Is Required for Lipid Accumulation, Basal
Lipolysis, and Glucose Uptake in Mature Adipocytes
We next focused on the effects of DEGS1 inhibition in
fully differentiated adipocytes by treating isolated mature
adipocytes—from the gonadal WAT of C57BL/6 mice—
with C8-CPPC for 24 h. C8-CPPC caused a decrease in the
expression of lipid metabolism genes as well as an increase
in antioxidant genes (Supplementary Fig. 7), recapitulating
our observations in 3T3-L1 preadipocytes.
We further investigated the effects of inhibiting DEGS1
on lipolytic activity and insulin signaling, and measured
adiponectin expression as a representative fingerprint
of global adipocyte homeostasis in mature differentiated
3T3-L1 adipocytes. Thus, we observed that basal lipolytic
activity was decreased in mature differentiated 3T3-L1
adipocytes when treated with C8-CPPC in nonstimulated
conditions (Fig. 6A). Systematic evaluation of the lipolytic
axis showed that, under basal conditions, phosphorylation of
Ser565 was also substantially increased by C8-CPPC con-
comitantly with a minor downregulation of Ser660 phosp-
horylation (Fig. 6B–D), suggesting a decreased HSL activity.
Moreover, total levels of HSL were also decreased in
C8-CPPC–treated cells. These data suggest that pharmaco-
logical inhibition of DEGS1 in mature adipocytes disrupts
the lipolytic response under nonstimulated conditions, a de-
fect that was superseded in the presence of NE.
Finally, we characterized the effects of pharmacological
inhibition of DEGS1 on insulin signaling in 3T3-L1 mature
adipocytes treated with C8-CPPC for 48 h, as described
above, and subsequently incubated in the presence of
increasing doses of insulin. No major differences were
observed in the phosphorylation of AKT in C8-CPPC–treated
Figure 2—A: mRNA expression of degs1 in 3T3-L1 treated with short hairpin RNA (shRNA) against degs1. B and C: Cell proliferation (XTT
and BrdU assays every 24 h until 96 and 72 h, respectively). D: mRNA expression of Cdk2, Bcl2, Bax, and Caspase3. E: Apoptosis and cell
death rate. F: Protein expression of Cdk2. G: Oxygen consumption rate. H: mRNA expression of antioxidant machinery genes. I: Reactive
oxygen species production. J: Mitochondria levels. All these experiments were perfomed in degs1 KD and WT 3T3-L1 cells. Values are the
mean 6 SEM of three separate experiments performed in triplicate. ETC, electron transport chain; MFI, mean fluorescence intensity; PI,
propidium iodide. *P < 0.05.
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cells after acute insulin stimulation (Fig. 6E). However,
we found that Glut4 protein levels were increased in
C8-CPPC–treated cells, suggesting that glucose uptake
may be increased (Fig. 6F). Interestingly, we also did not
observe any differences in either adiponectin levels in re-
sponse to C8-CPPC or in AMPK phosphorylation, a known
inducer of adiponectin, although increased levels of total
AMPK were observed (Fig. 6G and H).
Pharmacological and Genetic Inhibition of DEGS1
Increases DhCer/Cer Ratio in 3T3-L1 Cells
We confirmed that C8-CPPC increased the DhCer/Cer
ratio in 3T3L-1 preadipocytes upon the inhibition of
DEGS1 (Fig. 4E). Similarly, degs1 KD preadipocytes (day 0)
exhibited an increased DhCer/Cer ratio versus controls
(Supplementary Fig. 8A). Downregulation of degs1
expression in degs1 KD cells was accompanied by a down-
regulation of serine palmitoyltransferase (sptlc1) and Cer
synthase 6 (Cers6) (Supplementary Fig. 8A), suggestive of
a homeostatic readjustment of the biosynthetic pathway
to compensate for the dysfunction of degs1. Other genes
related to Cer homeostasis such as neutral ceramidase
(ncdase) and glycosylceramide synthase (gcs) were also
downregulated.
Curiously, at day 9, degs1 KD cells, despite impaired
differentiation, showed a complete restoration of the
DhCer/Cer ratio (indicated by the normalization of the
Cer pool) (Supplementary Fig. 8B). This could be partially
explained by a compensation mechanism, mediated by
downregulation of neutral ceramidases and the conversion
of sphyngomyelins to Cers (upregulation of sphyngomye-
linase 2) (Supplementary Fig. 8B).
Figure 3—A: mRNA expression of degs1 in 3T3-L1 cells during adipocyte differentiation. B: Lipid accumulation at day 9 of differentiation,
Oil Red O staining. C: mRNA expression of PREF1 in WT and degs1 KD cells during differentiation. D: mRNA expression of genes involved
in adipocyte differentiation and lipid accumulation. Values are the mean 6 SEM of three separate experiments performed in triplicate. FAS,
fatty acid synthase; Insig, insulin-induced gene; LPL, lipoprotein lipase. *P < 0.05.
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The Impairment of Adipocyte Differentiation During
Early Adipogenesis by DEGS1 Inhibition Is
Recapitulated by DhCers Per Se
We finally sought to validate whether DhCer by itself could
mediate the effects of DEGS1 inhibition on adipocyte
differentiation in our models of genetic or pharmacological
inhibition of degs1. 3T3-L1cells were treated with C2DhCer
during 1) the MCE at time 0 and 2) at day 3 after differ-
entiation. DhCer inhibited lipid accumulation (Fig. 7A) and
the expression of genes involved during the early stages of
adipogenesis (Fig. 7B).
Since synthetic sphingolipid analogs are known to
modulate PPAR activity (22), we investigated whether
both C2DhCer and C16DhCer could exert a repressive
effect on PPARg activation in the presence of the PPARg
ligands (Fig. 7C). Our results show that DhCer can also
block the ligand-mediated transactivation of PPARg. Sim-
ilar results were obtained with Cers, indicating that these
effects were not a consequence of the unsaturation of the
sphingoid moiety (data not shown).
DISCUSSION
The DhCer/Cer ratio has an important homeostatic
regulatory role in the cell, contributing to cell survival,
autophagy, and oxidative stress (12,13). Here we identify
DEGS1 as an essential metabolic enzyme, which is dysreg-
ulated in obese states and contributes to AT dysfunction.
Our complementary in vitro and in vivo approaches reveal
that reduced DEGS1 function impairs adipogenesis and
lipogenesis programs, and increases oxidative stress.
DEGS1 is expressed in WAT and correlates in rodents
with fat mass in healthy states, an association that is
Figure 4—3T3-L1 cells treated with C8-CPPC and/or rosiglitazone. A and B: mRNA expression of genes involved in adipocyte differen-
tiation and lipid accumulation at 24 and 48 h after induction. C: Protein expression levels of PPARg2 and cEBPa. D: Lipid content after 48
and 96 h of differentiation. Values are the mean 6 SEM of two separate experiments performed in triplicate. One-way ANOVA was used to
analyze the statistical significance between treatments at 24 and 48 h. Significant differences (Duncan test, P < 0.05) are indicated with
different letters. E: DhCer, Cer, and hexosylceramide (HexCer) levels after 48 h of differentiation. Values are the mean 6 SEM of two
separate experiments performed in triplicate. cEBP, CCAAT/enhancer binding protein; d, day; FITC, fluorescein isothiocyanate; MFI, mean
fluorescence intensity; Rosi, rosiglitazone. *P < 0.05.
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disrupted in severe forms of obesity. The expression of
DEGS1 in liver or muscle is not affected by obesity, fur-
ther indicating that the WAT is particularly susceptible to
changes in Cer metabolism in obese states. The relevance
to human obesity is confirmed by the downregulation of
DEGS1 in the AT of MO patients, and by recent reports
(23,24) showing that DhCer rather than Cer content pos-
itively correlates with BMI and waist circumference in
cohorts of overweight obese subjects. To date, only a single
functional mutation in the degs1 gene has been reported
in humans, where patients demonstrate increased serum
DhCer, decreased cholesterol esters, and decreased waist-
to-hip ratio (25). Globally considered, these data suggest
the existence of an association between DEGS1 function
and fat mass.
The molecular mechanism leading to the defective AT
expression of degs1 in human and rodent obesity is un-
known. Here, we have shown that tumor necrosis factor-a,
a mediator of obesity-induced inflammation and insulin
resistance, decreases the transcriptional expression of
degs1 in cultured adipocytes, which suggests that low
chronic inflammation may contribute to DEGS1 dysfunc-
tion. Other obesity-associated processes, such as in-
creased oxidative stress and hypoxia, have been shown
to impair DEGS1 activity and increase DhCer levels (26).
Our results also show a positive association between
Figure 5—C8-CPPC inhibitor increases proliferation and decreases lipid accumulation in preadipocytes in vivo. Ten-week-old mice were
given a 45% HFD for 5 weeks before being treated intraperitoneally with vehicle or C8-CPPC inhibitor (2 mg/kg/day) over 9 days.
A: Representative images of immunofluorescence analysis of gonadal AT of control (vehicle) and C8-CPPC–treated mice are presented
with Pref-1 (cyan) and Ki67 (red, white arrows). Nuclei and lipids are respectively stained with Hoechst stain (blue) and BODIPY (green).
Scale bars: 100 or 20 mm. Quantification of preadipocytes (left graph) (percentage of Pref-1+ cells/total cells) and (right graph) Ki67+ (white
bars)/BODIPY+ (dark gray bars) cells among preadipocytes (Pref-1+ cells) (light gray bars). B: mRNA expression of preadipocyte markers
and pparg, degs1, adiponectin, caspase 3, and fas in gonadal AT of control and C8-CPPC–treated mice. n = 7–8 mice per experimental
group. Values are the mean 6SEM. *P < 0.05, ***P < 0.0001 vs. vehicle.
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Figure 6—A: Glycerol release in 3T3-L1 adipocytes exposed for 48 h to C8-CPPC and stimulated with NE for 6 h. B–D: Results from
Western blot analysis for phosphorylated (p) HSL/HSL ratio and total HSL in 3T3-L1 adipocytes exposed for 48 h to C8-CPPC and
stimulated with NE for 6 h. Graphs show the mean 6 SEM of two separated experiments: *P < 0.05. E: Effects of pharmacological
inhibition of DEGS1 on insulin (ins) signaling. Results from Western blot analysis for p-AKT and AKT in 3T3-L1 adipocytes exposed 48 or 72
h with C8-CPPC 1 mmol/L and increased concentrations of insulin (10–100 nmol/L) for 15 min. F and G: Results from Western blot analysis
for Glut4 and adiponectin in 3T3-L1 adipocytes exposed with C8-CPPC 0.5–1 mmol/L and insulin (100 nmol/L) for 48 h. H: Results from
Western blot analysis for AMPK in 3T3-L1 adipocytes exposed to C8-CPPC 0.5–1 mmol/L and insulin (Ins) (100 nmol/L), rosiglitazone (Rosi)
(1 nmol/L), and metformin (Metf) (100 nmol/L) for 48 h. aP < 0.05 vs. untreated cells (Ins, Rosi, or Metf effect); bP < 0.05 vs. 0 mmol/L
C8-CPPC (C8-CPPC effect). AU, arbitrary units; IOD, integrated optical density.
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levels of the proadipogenic pparg2 isoform and degs1
in AT, and, given the documented downregulation of
pparg2 in AT in obese insulin-resistant states, it is con-
ceivable that decreased levels of pparg2 may contribute
to the defective expression of degs1 associated with
obesity.
Studies in rodents have shown that the number of Cers
is increased in the WAT of animals fed an HFD (5) con-
comitantly with the onset of insulin resistance (6). Results
from ob/ob mice and obese human studies are more un-
clear, where both increased or decreased levels of Cers
have been reported (7,8). This suggests that Cer synthesis
may be dependent on the severity of the obese state and
the strength of the adaptive homeostatic responses
attempting to restore their normal balance.
Our pharmacological and gene ablation studies have
shown that inhibition of DEGS1 is associated with oxida-
tive stress, cellular death, impaired adipocyte differentia-
tion, impaired lipid accumulation, and impaired basal
lipolysis in mature adipocytes.
Our in vitro studies revealed that the defect in the
adipogenesis program caused by depletion of DEGS1
occurs during the early stages of adipogenesis (MCE)
when PPARg controls the expression of genes that regu-
late the cell cycle by directly interacting with cyclin D3.
Another cyclin involved in adipocyte differentiation is
cyclin D1, and here we show that downregulation of
DEGS1 blocks PPARg activity and cyclins such as D1,
D3, E, as well as decreasing cdk2, which modulates PPARg
activity during adipogenesis. These data are consistent
Figure 7—A and B: DhCers impair adipocyte differentiation during early adipogenesis. 3T3-L1 preadipocytes treated with C2DhCer
(50 mmol/L) for a period of 48 h at day 0 or day 3 of differentiation. Oil Red O staining and mRNA expression of adipogenesis and lipid
metabolism genes. Values are the mean 6 SEM of two separate experiments performed in triplicate. *P < 0.05 vs. control. C: DhCers
decrease ligand-mediated PPARg transactivation. Cells were treated with DMSO as a control group and rosiglitazone 10 mmol/L, GW1929
10 mmol/L, and C2 and C16DhCers and Cers 100 mmol/L as indicated. Graphs represent the average of three independent experiments.
*P < 0.05 vs. control cells; #P < 0.05 vs. rosiglitazone; &P < 0.05 vs. GW1929. CTL, control.
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with studies showing that downregulation of degs1 by
small interfering RNA inhibits cell growth and arrests
the cell cycle in cancer cells (12) and where its overexpres-
sion increased cell migration and metastasis (27).
The pharmacological inhibition of DEGS1 in vivo
validated the results obtained in vitro and strengthened
the concept that functional degs1 is required for the full
differentiation of preadipocytes into mature adipocytes.
We also provide evidence that both pharmacological
and genetic ablation of degs1, which, according to our
results in in vitro models, may directly block adipocyte
differentiation and lipid deposition, certainly increased
DhCer levels in in vitro models. In this line, our results
showed that the treatment of adipocytes with DhCer
causes impaired adipogenesis and lipid accumulation.
This effect on lipid accumulation was more severe
when the treatment was administered during the first
3 days of differentiation, suggesting a direct impact of
DhCer accumulation during early stages of adipogenesis.
We also provide evidence showing that accumulation of
DhCers can also directly repress the transcriptional ac-
tivity of PPARg and hence could contribute to impair-
ment of the capacity of the preadipocytes to develop
a full adipogenic program.
These observations strengthen the concept that DhCers
are not merely inert precursors of Cers. Nevertheless, the
molecular mechanism linking DhCers accumulation and
dysregulation of the cell cycle and other cellular events
remains elusive. One possible mechanism is that changes
in the DhCer/Cer ratio may disrupt membrane-dependent
structures by altering the levels of cholesterol and/or
caveolin in lipid rafts, which are known to be highly
sensitive to a sphingomyelin pool. Alternatively, changes
in the DhCer/Cer ratio may disturb the global phospho-
lipidome, potentially altering membrane-associated pro-
cesses relevant to adipocyte function. These are important
questions to address in future research.
In summary, our results indicate that defects in DEGS1
in the context of the metabolic syndrome may compro-
mise AT expansion and function through the combined
inhibition of adipogenesis, promotion of cell death, and
oxidative stress due to the direct accumulation of DhCers.
Thus, our data suggest that the selective manipulation of
DEGS1 and/or its substrates in WAT may be a pathophy-
siologically advantageous strategy to improve AT homeo-
stasis and ameliorate the burden of obesity-associated
metabolic complications.
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